AR122901A1 - Composiciones que tienen aplicaciones neuroregenerativas - Google Patents

Composiciones que tienen aplicaciones neuroregenerativas

Info

Publication number
AR122901A1
AR122901A1 ARP210101906A ARP210101906A AR122901A1 AR 122901 A1 AR122901 A1 AR 122901A1 AR P210101906 A ARP210101906 A AR P210101906A AR P210101906 A ARP210101906 A AR P210101906A AR 122901 A1 AR122901 A1 AR 122901A1
Authority
AR
Argentina
Prior art keywords
injury
lactoferrin
neuroregenerative
compositions
applications
Prior art date
Application number
ARP210101906A
Other languages
English (en)
Inventor
Thomas Barnett
David Ross
Original Assignee
Grifols Worldwide Operations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Worldwide Operations Ltd filed Critical Grifols Worldwide Operations Ltd
Publication of AR122901A1 publication Critical patent/AR122901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

En el presente documento se dan a conocer composiciones farmacéuticas que contienen transferrina y/o lactoferrina para utilizar en la promoción y/o inducción de la generación de nuevas células neurales en un paciente que ha sufrido un evento neurodegenerativo derivado, como mínimo, de una de una lesión cerebral traumática, una lesión cerebral no traumática, una lesión en la médula espinal, una lesión del nervio periférico o una neuropatía periférica. De manera ideal, la transferrina y/o lactoferrina tienen una saturación baja de hierro.
ARP210101906A 2020-07-08 2021-07-07 Composiciones que tienen aplicaciones neuroregenerativas AR122901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063049516P 2020-07-08 2020-07-08

Publications (1)

Publication Number Publication Date
AR122901A1 true AR122901A1 (es) 2022-10-12

Family

ID=77126776

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101906A AR122901A1 (es) 2020-07-08 2021-07-07 Composiciones que tienen aplicaciones neuroregenerativas

Country Status (14)

Country Link
US (1) US20230265167A1 (es)
EP (1) EP4178553A1 (es)
JP (1) JP2023532514A (es)
KR (1) KR20230038194A (es)
CN (1) CN115916167A (es)
AR (1) AR122901A1 (es)
AU (1) AU2021305384A1 (es)
BR (1) BR112022026210A2 (es)
CA (1) CA3182956A1 (es)
CL (1) CL2022003596A1 (es)
IL (1) IL299182A (es)
MX (1) MX2022016226A (es)
TW (1) TW202216185A (es)
WO (1) WO2022008586A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4052723A1 (en) * 2021-03-02 2022-09-07 Grifols Worldwide Operations Limited Alpha-1 antitrypsin dosing regimen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100577798C (zh) * 2007-01-30 2010-01-06 中国人民解放军军事医学科学院基础医学研究所 细胞因子和化合物构成的组方，其促进神经再生作用及在神经系统疾患研究和诊治中的作用
WO2012149111A1 (en) * 2011-04-26 2012-11-01 The Regents Of The University Of California Methods of promoting cns neuronal repair by inhibiting lrp-1
WO2013068504A1 (en) * 2011-11-11 2013-05-16 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol Apotransferrin for the treatment of brain stroke
EP3795171B1 (en) 2014-07-11 2024-04-10 Grifols Worldwide Operations Limited Transferrin for use in kidney transplantation

Also Published As

Publication number Publication date
EP4178553A1 (en) 2023-05-17
CL2022003596A1 (es) 2023-07-07
IL299182A (en) 2023-02-01
CA3182956A1 (en) 2022-01-13
JP2023532514A (ja) 2023-07-28
CN115916167A (zh) 2023-04-04
BR112022026210A2 (pt) 2023-01-17
TW202216185A (zh) 2022-05-01
US20230265167A1 (en) 2023-08-24
AU2021305384A1 (en) 2023-02-02
KR20230038194A (ko) 2023-03-17
WO2022008586A1 (en) 2022-01-13
MX2022016226A (es) 2023-02-01

Similar Documents

Publication Publication Date Title
PE20191303A1 (es) Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2
CR20190468A (es) Métodos para tratar enfermedades y trastornos mediados por completo
CL2022003596A1 (es) Composiciones que tienen aplicaciones neuroregenerativas
BR112015006093A2 (pt) combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington
BR112022007677A2 (pt) L-asparaginase recombinante
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112018074454A2 (pt) composições e métodos de uso de nintedanib para tratar doenças oculares com neovascularização anormal
BR112021025676A2 (pt) Composições e métodos para tratar uma afecção mediada por th2 com o uso de prevotella
PH12016500715A1 (en) Di-isopropyl-phosphinoyl-alkane (dapa) compounds as topical agents for the treatment of sensory discomfort
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
CL2017002846A1 (es) Métodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t.
DOP2021000251A (es) Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b
CL2023001580A1 (es) Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección
BR112022019932A2 (pt) Composições para saúde metabólica
AR112538A1 (es) Métodos para el tratamiento de distrofia muscular
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
EA201800536A1 (ru) Фармацевтическая композиция, которая включает энергетически обработанный нейтральный носитель, и связанные с ним методы лечения
PH12020551179A1 (en) Methods for treating mitochondrial disorder
BR112019024667A2 (pt) Uso de um agente bioativo, e, de uma composição
CL2022003591A1 (es) Composiciones que tienen aplicaciones neuroregenerativas
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
CL2023002914A1 (es) Dosificación y administración de l-asparaginasa recombinante
DOP2022000095A (es) Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
AR110947A1 (es) Tratamiento de degeneración de la retina mediante el uso de células progenitoras